18-Fluorodeoxyglucose imaging with positron emission tomography and single photon emission computed tomography: Cardiac applications

Seminars in Nuclear Medicine

Volumn 30, Issue 4, 2000, Pages 281-298

  Bax, Jeroen J ^a,b,c   Patton, James A ^a,b,c   Pldermans, Don ^a,b,c   Elhendy, Abdou ^a,b,c   Sandler, Martin P ^a,b,c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ACIPIMOX; AMMONIA; CARBON 11; FLUORODEOXYGLUCOSE F 18; GLUCOSE; INSULIN; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NITROGEN 15; OXYGEN 15; RUBIDIUM 82; THALLIUM 201; WATER;

CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; DRUG UPTAKE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE METABOLISM; HEART MUSCLE REVASCULARIZATION; HUMAN; INTERMETHOD COMPARISON; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 0033770076     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2000.9543     Document Type: Article

References (103)

1. Chronic heart failure in the United States. A manifestation of coronary artery disease
2. Medical management of heart failure secondary to coronary artery disease
3. Donor availability as the primary determinant of the future of heart transplantation
4. Management of heart failure. III. The role of revascularization in treatment of patients with moderate or severe left ventricular systolic dysfunction
5. Late results of surgical and medical therapy for patients with coronary artery disease and depressed left ventricular function
6. The Multicenter Postinfarction Research Group: Risk stratification and survival after myocardial infarction
7. Thallium-201 for assessing myocardial viability
8. Assessment of myocardial viability
9. Current diagnostic techniques of assessing viability in patients with hibernating and stunned myocardium
10. Assessment of tissue viability: Clinical demand and problems
11. The viable myocardium: Epidemiology, detection, and clinical implications
12. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: Comparison of pooled data
13. Positron emission tomography for the assessment of myocardial viability
14. The clinical role of metabolic imaging of the heart by positron emission tomography
15. Fluorine-18-fluorodeoxyglucose cardiac imaging using a modified scintillation camera
16. Fluorine 18-labeled fluorodeoxy-glucose myocardial single-photon emission computed tomography: An alternative for determining myocardial viability
17. Cardiac metabolism
18. Relationship between carbohydrate and lipid metabolism and the energy balance of the heart muscle
19. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart
20. Myocardial metabolism in ischemic heart disease: Basic principles and application to imaging by positron emission tomography
21. 14C] glucose and L-[1,2,3-13C3] lactate: A new approach for investigating human myocardial metabolism during ischemia
22. Effects of regional ischemia on metabolism of glucose and fatty acids: Relative rates of aerobic and anaerobic energy production during myocardial infarction and comparison with effects of anoxia
23. Methodology governing the assessment of myocardial glucose metabolism by positron emission tomography and fluorine 18-labeled fluorodeoxyglucose
24. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo
25. Positron emission tomography myocardial viability studies in patients with diabetes mellitus
26. Relationship between blood glucose levels and F-18 fluorodeoxyglucose image quality in cardiac PET FDG studies
27. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography
28. Myocardial glucose uptake in patients with insulin-dependent diabetes mellitus assessed by positron emission tomography
29. The use of low-dose intravenous insulin in clinical myocardial F-18 FDG PET scanning
30. A simplified intravenous glucose loading protocol for fluorine-18 fluorodeoxyglucose cardiac single-photon emission tomography
31. Enhancement of myocardial [fluorine-18] fluorodeoxyglucose uptake by a nicotinic acid derivative
32. Bioavailability and pharmacokinetics of acipimox, a new antilipolytic and hypolipidaemic agent
33. FDG SPECT image quality using acipimox; comparison with oral glucose loading and hyperinsulinemic glucose clamping
34. Role of T1-201 and PET imaging in evaluation of myocardial viability and management of patients with coronary artery disease and left ventricular dysfunction
35. Regional perfusion, glucose metabolism, and wall motion in patients with chronic electrocardiographic Q wave infarctions: Evidence for persistence of viable tissue in some infarct regions by positron emission tomography
36. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography
37. Metabolic responses of hibernating and infarcted myocardium to revascularization
38. Myocardial blood flow, glucose uptake and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction. Implications for the pathophysiology of chronic hibernation
39. PET using fluorine-18 deoxyglucose in evaluation of coronary artery bypass grafting
40. Comparison of carbon-11-acetate with fluorine-18-fluorodeoxy-glucose for delineating viable myocardium by positron emission tomography
41. Assessment of myocardial viability in chronic coronary artery disease using technetium-99m sestamibi SPECT. Correlation with histologic and positron emission tomographic studies and functional follow-up
42. Prediction of reversible ischemia after revascularization. Perfusion and metabolic studies with positron emission tomography
43. Myocardial viability: Fluorine-18-deoxyglucose positron emission tomography in prediction of wall motion recovery after revascularization
44. Predictive value of low dose dobutamine transesophageal echocardiography and fluorine-18 fluorodeoxyglucose positron emission tomography for recovery of regional left ventricular function after successful revascularization
45. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile SPECT and fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease
46. Improvement of severely reduced left ventricular function after surgical revascularization in patients with preoperative myocardial infarction
47. Metabolic activity in the areas of new fill-in after thallium-201 reinjection: Comparison with positron emission tomography using fluorine-18-deoxyglucose
48. Histological alterations in chronically hypoperfused myocardium. Correlation with PET findings
49. Myocardial viability assessment in ischemic cardiomyopathy: Benefits of coronary revascularization
50. Structural and metabolic correlates of the reversibility of chronic left ventricular ischemic dysfunction in humans
51. Regional myocardial blood flow, glucose utilization and contractile function before and after revascularization and ultrastructural findings in patients with chronic coronary artery disease
52. Preoperative positron emission tomographic viability assessment and preioperative and postoperative risk in patients with advanced ischemic heart disease
53. Recovery of regional left ventricular dysfunction after coronary revascularization. Impact of myocardial viability assessed by nuclear imaging and vessel patency at follow-up angiography
54. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction
55. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography
56. Prediction by postexercise fluoro-18 deoxyglucose positron emission tomography of improvement in exercise capacity after revascularization
57. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy
58. Prognostic value of an increase in fluorine-18 deoxyglucose uptake in patients with myocardial infarction: Comparison with stress thallium imaging
59. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium after myocardial infarction. Relative efficacy of medical therapy and revascularization
60. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease
61. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorordeoxyglucose positron emission tomography
62. Prolonged myocardial hibernation exacerbates cardiomyocyte degeneration and impairs recovery of function after revascularization
63. F-18-fluorodeoxyglucose PET imaging alters clinical decision making in patients with impaired ventricular function
64. Performance characteristics of a 511-keV collimator for imaging positron emitters with a standard gamma-camera
65. Feasibility of planar fluorine-18-FDG imaging after recent myocardial infarction to assess myocardial viability
66. Predictive value of planar 18F-fluorodeoxyglucose imaging for cardiac events in patients after acute myocardial infarction
67. Is planar thallium-201/fluorine-18 fluorodeoxyglucose imaging a reasonable clinical alternative to positron emission tomographic viability scanning?
68. Myocardial metabolic imaging by means of fluorine-18 deoxyglucose/ technetium-99m sestamibi dual-isotope single-photon emission tomography
69. Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for the detection of myocardial viability
70. FDG-SPECT: Correlation with FDG-PET
71. Comparison of myocardial uptake of F18-fluorodeoxyglucose imaged with positron emission tomography and single photon emission computed tomography
72. Myocardial viability studies using fluorine-18-FDG SPECT: A comparison with fluorine-18-FDG PET
73. 18F]fluorodeoxyglucose single photon emission computed tomography. Can it replace PET and thallium SPECT for the assessment of myocardial viability?
74. Evaluation of myocardial ischemia using a rest metabolism/stress perfusion protocol with fluorine-18 deoxyglucose/technetium-99m MIBI and dual-isotope simultaneous-acquisition single-photon emission computed tomography
75. Dobutamine stress echocardiography and technetium-99m-tetrofosmin/ fluorine 18-fluorodeoxyglucose single-photon emission computed tomography and influence of resting ejection fraction to assess myocardial viability in patients with severe left ventricular dysfunction and healed myocardial infarction
76. Prediction of recovery of myocardial dysfunction after revascularization. Comparison of fluorine-18 fluorodeoxyglucose/thallium-201 SPECT, thallium-201 stress-reinjection SPECT and dobutamine echocardiography
77. Prediction of improvement of contractile function in patients with ischemic ventricular dysfunction after revascularization by F18-fluorodeoxyglucose SPECT
78. Feasibility of myocardial F18-fluorodeoxyglucose single photon emission computed tomography in patients with noninsulin-dependent diabetes mellitus
79. F18-fluorodeoxyglucose single-photon emission computed tomography predicts functional outcome of dyssynergic myocardium after surgical revascularization
80. Prediction of improvement of regional left ventricular function after revascularization using different perfusion-metabolism criteria
81. Predictive value of Tc-99m-tetrofosmin/18-FDG dual-isotope SPECT and dobutamine stress echocardiography for the functional outcome after revascularization
82. The magnitude of improvement of LVEF post-revascularization is determined by the extent of viable tissue
83. Prognostic value of FDG imaging using SPECT in patients with severe left ventricular dysfunction
84. Long-term prognostic value of FDG SPECT in patients with ischaemic left ventricular dysfunction
85. Identification of viable myocardium in patients with chronic coronary artery disease and left ventricular dysfunction. Comparison of thallium scintigraphy with reinjection and PET imaging with 18-F-Fluorodeoxyglucose
86. Concordance and discordance between stress-redistribution-reinjection and rest-redistribution thallium imaging for assessing viable myocardium. Comparison with metabolic activity by positron emission tomography
87. Comparison of fluorine-18-FDG with rest-redistribution thallium-201 SPECT to delineate viable myocardium and predict functional recovery after revascularization
88. Significance of defect severity in technetium-99m-MIBI SPECT at rest to assess myocardial viability: Comparison with fluorine-18-FDG PET
89. Comparison of sestamibi single-photon emission computed tomography with positron emission tomography for estimating left ventricular myocardial viability
90. Myocardial viability in patients with chronic coronary artery disease. Comparison of 99mTc-Sestamibi with thallium reinjection and [18F]fluorodeoxyglucose
91. Positron emission tomography detects evidence of viability in rest technetium-99m sestamibi defects
92. 18F-fluorodeoxyglucose
93. Assessment of myocardial viability by dobutamine stress echocardiography
94. Assessment of viable myocardium by dobutamine transesophageal echocardiography and comparison with fluorine-18 fluorodeoxyglucose positron emission tomography
95. 18F-fluorodeoxyglucose SPECT vs low-dose dobutamine echocardiography
96. Effects of dobutamine stimulation on myocardial blood flow, glucose metabolism, and wall motion in normal and dysfunctional myocardium
97. Evaluation of perfusion and metabolism in dobutamine-responsive myocardium
98. Predictive value of dobutamine echocardiography and positron emission tomography in identifying hibernating myocardium in patients with postischaemic heart failure
99. Agreement and disagreement between 'metabolic viability' and 'contractile reserve' in akinetic myocardium
100. Hibernating myocardium: Morphological correlates of inotropic stimulation and glucose uptake
101. Delayed recovery of hibemating myocardium after surgical revascularization: Implications for discrepancy between metabolic imaging and dobutamine echocardiography for assessment of myocardial viability
102. The clinical role of positron emission tomography in management of the cardiac patient
103. Simultaneous coincidence and Tc99m SPECT imaging using a dual purpose camera with collimators and a cross-talk correction algorithm